TAM
TARA icon

Tiverton Asset Management’s Protara Therapeutics TARA Stock Holding History

Tiverton Asset Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-325
Closed -$30K – 665
2018
Q4 		$30K Buy
+325
New +$23K ﹤0.01% 474
2016
Q4 		– Sell
-4,055
Closed -$1.51M – 196
2016
Q3 		$1.51M Sell
4,055
-8,394
-67% -$2.95M 0.12% 136
2016
Q2 		$28.2M Buy
12,449
+5,830
+88% +$1.74M 1.19% 23
2016
Q1 		$2.05M Sell
6,619
-989
-13% -$319K 0.07% 140
2015
Q4 		$4.72M Sell
7,608
-1,767
-19% -$1.04M 0.15% 113
2015
Q3 		$5.22M Hold
9,375
– – 0.12% 119
2015
Q2 		$6.7M Hold
9,375
– – 0.13% 123
2015
Q1 		$4.36M Hold
9,375
– – 0.09% 126
2014
Q4 		$3.9M Buy
+9,375
New +$3.78M 0.08% 121

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tiverton Asset Management's TARA Position: Q1 2019 in Review

Tiverton Asset Management sold out of Protara Therapeutics (TARA) in Q1 2019, closing a stake of 325 shares — an estimated $30K sold.

Tiverton Asset Management first reported a position in TARA in Q4 2014 and held it in 9 quarters. The position peaked at $28.2M in Q2 2016. 14 funds tracked by Wall St. Rank hold TARA as of Q1 2019.

  • Tiverton Asset Management reported no remaining Protara Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 325 Protara Therapeutics shares in Q1 2019, an estimated $30K.
  • Tiverton Asset Management first reported a position in Protara Therapeutics in Q4 2014 and held it in 9 quarters.
  • Tiverton Asset Management's Protara Therapeutics position peaked at $28.2M in Q2 2016.
  • 14 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2019.

Based on Tiverton Asset Management's 13F filing for Q1 2019, filed 13 May 2019.